Celltrion aims for KRW 5T sales with 'ADC‧CDMO'

Announced a strategic plan for developing biosimilars and new drugs…will disclose new pipelines, such as ADC

Expected to generate a total of KRW 3.5 trillion in sales for 2024…aims for 5 trillion sales next year, based on Zymfentra sales

Celltrion will secure a manufacturing plant by incorporating wholly owned subsidiary

Celltrion aims to achieve KRW 5 trillion in sales by 2025 based on the growth of the biosimilar pipeline and new business operations.

 

Celltrip Group President Seo Jung-jin (center) and Celltrion CEO Seo Jin-seok (right).

Celltrip Group President Seo Jung-jin and Celltrion CEO Seo Jin-seok announced on September 9th that they have participated in the 'Morgan Stanley 22nd Annual Global Healthcare Conference' in the United States on September 6th and presented the group's strategic plan for the future.

 

Morgan Stanley Global Healthcare Conference is an event hosted by the global investment bank (IB) Morgan Stanley.

 

It invites promising biotechnology companies worldwide and provides an opportunity to meet with global institutional investors.

 

This year marks the 22nd event.

 

Celltrion Group participated in a presentation session titled 'From Pioneer to Innovator.' The group presented the group's new drug pipeline and disclosed the ongoing development and schedule of follow-up biosimilars.

 

For its biosimilar business sector, Celltrion plans to receive 11 product approvals by 2025 and secure a 22-product portfolio by 20203 to expand market dominance.

 

In addition to studying autoimmune diseases, the group will expand the treatment field to asthma·rash, ophthalmology, and metabolic bone disease.

 

Celltrion also focuses on strengthening collaboration with prescription benefit managers (PBM) to increase sales efficiency.

 

Celltrion has secured a sales expansion foundation by signing agreements with the top 3 PBM companies over prescription reimbursement within six months after the launch of Zymfentra in the United States in March.

 

According to the company, target sales for Zymfentra will likely reach KRW 250 billion this year.

 

Additionally, other biosimilar products have a continuously expanding market presence.

 

As a result, the company is expecting to reach target sales of KRW 3.5 trillion.

 

The analysis suggests that Celltrion can reach KRW 5 trillion in sales next year if Zymfentra continues expanding its market presence as planned.

 

Furthermore, Celltrion has a high expectation for improving revenue as its merger with Celltrion Healthcare is nearing completion.

 

Celltrion emphasized that the temporarily increased cost to sales rate upon merger is quickly being reduced, and the sales and margin rate will rise with time.

 

Celltrion will start developing antibody-drug conjugates (ADC) and multispecific antibodies as a new drug pipeline this year.

 

By next year, the company will announce new drug candidates that are 'best-in-class.' Celltrion has selected three ADCs and three multispecific antibodies and started development.

 

The company aims to commercialize its first product by 2029.

 

Celltrion will disclose two new ADCs nearing completion and plans to enter clinical stages by next year.

 

President Seo stated, "We must build additional manufacturing plants to secure product manufacturing capacity for a sustainable future.

 

The company will decide on securing new plants in South Korea or overseas within this year," adding, "New facilities will be incorporated as a wholly owned subsidiary, and the group will use those for CDMO businesses."